Tocilizumab as first treatment option in optic neuropathy secondary to Graves’ orbitopathy

ABSTRACT

Dysthyroid optic neuropathy (DON) is one of the complications that can affect Graves’ orbitopathy (GO) patients. Its prevalence is estimated at less than 5%. It is usually treated with intravenous steroids, radiotherapy or orbital decompression.

Tocilizumab has been proposed as a treatment option in cases of GO refractory to steroid treatment, with good clinical results. Our aim is to report the case of a patient with optic neuropathy secondary to GO treated with tocilizumab as primary treatment option.

KEYWORDS:

• Decompression
• dysthyroid optic neuropathy
• Graves’ orbitopathy
• steroids
• tocilizumab

Disclosure statement

The authors report no conflicts of interest. The author alone is responsible for the content and writing of the article.